IDNA news

iShares Genomics Immunology and Healthcare · Biotechnology · Genomics & Biotech Innovation

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

24/7 Wall St. · 28 Oct 2026, 16:04 UTC
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
13.1% of IDNA
TheStreet · 28 Oct 2026, 19:33 UTC
Breakthrough cancer vaccine catches Wall Street's attention
8.1% of IDNA
Seeking Alpha · 28 Oct 2026, 21:30 UTC
Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript | Seeking Alpha
4.2% of IDNA
The Wall Street Journal · 28 Oct 2026, 20:17 UTC
Here's Why Moderna's CEO Isn't Fazed by Its Cancer-Vaccine Selloff
4.2% of IDNA
Where to buy IDNA
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Aol · 28 Oct 2026, 19:44 UTC
Genmab Stock Hits 52-Week High - Here's Why
4.2% of IDNA
RTTNews · 28 Oct 2026, 19:16 UTC
Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%
4.2% of IDNA
Where to buy IDNA
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Investing.com · 28 Oct 2026, 14:08 UTC
Why is Twist Bioscience stock surging today? By Investing.com
4.8% of IDNA
Benzinga · 28 Oct 2026, 17:44 UTC
Genmab Stock Hits 52-Week High - Here's Why - Genmab (NASDAQ:GMAB)
4.2% of IDNA
Benzinga · 28 Oct 2026, 19:32 UTC
Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings - Amazon.com (NASDAQ:AMZN), Intel (NASDAQ:INTC
3.9% of IDNA
wallstreet:online · 28 Oct 2026, 12:05 UTC
Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies
4.8% of IDNA
The Boston Globe · 27 Oct 2026, 17:43 UTC
Moderna CEO on what's next after success in cancer vaccine
8.1% of IDNA
The Boston Globe · 27 Oct 2026, 17:40 UTC
After a cancer vaccine's first success, the race is on to expand the impact
8.1% of IDNA
Seeking Alpha · 28 Oct 2026, 16:22 UTC
Moderna: ESMO Answered The Science, Q3 Has To Answer The Money (NASDAQ:MRNA) | Seeking Alpha
4.2% of IDNA
RTTNews · 28 Oct 2026, 15:52 UTC
Genmab Shares Surge 30% On Phase 3 Head And Neck Cancer Trial Data
4.2% of IDNA
Investing.com · 28 Oct 2026, 15:42 UTC
Incyte earnings up next: Analysts eye loss amid pipeline gains By Investing.com
4.2% of IDNA
Seeking Alpha · 28 Oct 2026, 18:55 UTC
Roche: Valuation Leaves Limited Upside (OTCMKTS:RHHBF) | Seeking Alpha
3.8% of IDNA
Market Screener · 28 Oct 2026, 14:41 UTC
Adagene Inc. Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte?S Inca33890 in Patients with Microsatellite Stable Colorectal Cancer
4.2% of IDNA
Bloomberg Business · 28 Oct 2026, 14:28 UTC
Genmab Shares Hit Record as Cancer Trial Extends Drugmaker's Run
4.2% of IDNA
Seeking Alpha · 28 Oct 2026, 14:10 UTC
Genmab stock rises on Phase 3 cancer trial data (GMAB:NASDAQ) | Seeking Alpha
4.2% of IDNA
wallstreet:online · 28 Oct 2026, 13:45 UTC
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
4.2% of IDNA

IDNA news

Where to buy IDNA

Where to buy IDNA